These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

64 related articles for article (PubMed ID: 8605499)

  • 1. Surrogate markers of HIV infection.
    Can Commun Dis Rep; 1995 Dec; 21(24):215-6. PubMed ID: 8605499
    [No Abstract]   [Full Text] [Related]  

  • 2. Beta2 microglobulin as a surrogate marker for HIV infection: good correlation with CD4 counts.
    Wanchu A; Arora S; Bhatnagar A; Sud A; Bambery P; Singh S
    Indian J Pathol Microbiol; 2004 Apr; 47(2):298-301. PubMed ID: 16295507
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The prognostic value of virology and immunology markers in Chinese HIV-1 infected people].
    Lin X; Xu L; Shao Y
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 1999 Mar; 13(1):41-4. PubMed ID: 12759951
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma levels of viro-immunological markers in HIV-infected and non-infected Ethiopians: correlation with cell surface activation markers.
    Messele T; Brouwer M; Girma M; Fontanet AL; Miedema F; Hamann D; Rinke de Wit TF
    Clin Immunol; 2001 Feb; 98(2):212-9. PubMed ID: 11161977
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advances in HIV markers.
    Elliott EB
    Can Fam Physician; 1996 Nov; 42():2301-2. PubMed ID: 8939326
    [No Abstract]   [Full Text] [Related]  

  • 6. Managing HIV. Part 4: Primary therapy. 4.3 The laboratory in managing HIV infection.
    Dwyer DE; Adelstein S; Cunningham AL; Merigan TC
    Med J Aust; 1996 Mar; 164(5):301-3. PubMed ID: 8628167
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Surrogate markers of immune function in human immunodeficiency virus-infected patients: what are they surrogates for?
    Hengel RL; Kovacs JA
    J Infect Dis; 2003 Dec; 188(12):1791-3. PubMed ID: 14673756
    [No Abstract]   [Full Text] [Related]  

  • 8. Volunteers needed for study of HIV viral load test.
    Oncology (Williston Park); 1996 Apr; 10(4):449-50. PubMed ID: 8723276
    [No Abstract]   [Full Text] [Related]  

  • 9. Simple markers for initiating antiretroviral therapy among HIV-infected Ethiopians.
    Mekonnen Y; Dukers NH; Sanders E; Dorigo W; Wolday D; Schaap A; Geskus RB; Coutinho RA; Fontanet A
    Ethiop Med J; 2003 Jun; 41 Suppl 1():61-5. PubMed ID: 15227882
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A decade of research on the natural history of HIV infection: Part 1. Markers.
    Strathdee SA; O'Shaughnessy MV; Montaner JS; Schechter MT
    Clin Invest Med; 1996 Apr; 19(2):111-20. PubMed ID: 8697670
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HIV surrogate markers: new virologic and immunologic indicators.
    MacDougall DS
    J Int Assoc Physicians AIDS Care; 1997 Mar; 3(3):15-7. PubMed ID: 11364123
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunological and virological markers in HIV infection.
    Vella S
    AIDS Clin Care; 1995 May; 7(5):37-40. PubMed ID: 11362683
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship of neurological manifestations, CD4+ lymphocyte count and plasma viral load in HIV infected patients.
    Gochitashvili N; Tsertsvadze T; Gatserelia L; Abashidze L; Sharvadze L
    Georgian Med News; 2005 Apr; (121):51-5. PubMed ID: 15908725
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Laboratory markers associated with progression of HIV infection.
    Kiepiela P; Smith AN; Rosenberg E
    Best Pract Res Clin Obstet Gynaecol; 2005 Apr; 19(2):243-54. PubMed ID: 15778113
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Possible biochemical impact of malaria infection in subjects with HIV co-infection in Anambra state, Nigeria.
    Onyenekwe CC; Ukibe N; Meludu SC; Ifeanyi M; Ezeani M; Onochie A; Ofiaeli N; Aboh N; Ilika A
    J Vector Borne Dis; 2008 Jun; 45(2):151-6. PubMed ID: 18592844
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The prognostic significance in HIV infection of immune activation represented by cell surface antigen and plasma activation marker changes.
    Plaeger S; Bass HZ; Nishanian P; Thomas J; Aziz N; Detels R; King J; Cumberland W; Kemeny M; Fahey JL
    Clin Immunol; 1999 Feb; 90(2):238-46. PubMed ID: 10080836
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The prognostic markers of survival and progression in HIV-1 infection. A study of CD4+ lymphocytes, antigen p24 and viral load during 3 years in a cohort of 251 patients].
    Rubio Caballero M; Nogués Biau A; Falguera Sacrest M; Puig Ganau T; Lecha N; Rubio Rivas C
    An Med Interna; 2000 Oct; 17(10):533-7. PubMed ID: 11109648
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monitoring of human immunodeficiency virus infection in resource-constrained countries.
    Crowe S; Turnbull S; Oelrichs R; Dunne A
    Clin Infect Dis; 2003 Jul; 37(Suppl 1):S25-35. PubMed ID: 12822129
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD4 monitoring in resource-limited settings. The state of the art at Bangkok.
    Huff B
    GMHC Treat Issues; 2004; 18(7-8):12-5. PubMed ID: 15473045
    [No Abstract]   [Full Text] [Related]  

  • 20. CD4 cell count and HIV DNA level are independent predictors of disease progression after primary HIV type 1 infection in untreated patients.
    Goujard C; Bonarek M; Meyer L; Bonnet F; Chaix ML; Deveau C; Sinet M; Galimand J; Delfraissy JF; Venet A; Rouzioux C; Morlat P;
    Clin Infect Dis; 2006 Mar; 42(5):709-15. PubMed ID: 16447119
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.